Abstract: Objective To explore the clinical features and survival of patients with metastatic pancreatic cancer in the real world, and analyze the prognostic factors. Methods A total of 55 patients admitted to Beijing Chaoyang Hospital, Capital Medical University from January 2017 to December 2020 were collected. SPSS 27.0 was used for overall survival (OS) and progression free survival (PFS) analysis by Kaplan-Meier method and Log rank test, and Cox regression model was used for multivariate analysis.  Results The median follow-up time was 55.3 months. We found that the median OS was 7.7 months, with 6-month, 1-year, and 2-year overall survival rates of 61.8%, 34.0% and 11.6%, respectively. First line therapy, Eastern Cooperative Oncology Group （ECOG） score, liver metastasis, pancreatectomy and carbohydrate antigen19-9 （CA19-9） value were significant prognostic factors for OS, and ECOG score, liver metastasis, CA19-9 value, efficacy and infection were significant prognostic factors for PFS in first line therapy.  Conclusion It is very important to take first line therapy for metastatic pancreatic cancer. We recommend selecting a more suitable treatment plan for patients based on their physical condition and clinical pathological characteristics. Our findings suggest that there is no significant difference in prognosis between different regimens. Next generation sequencing （NGS） examination is recommended for patients with metastatic pancreatic cancer, if targeting and immunotherapy opportunities are available to prolong survival. 

Key words: metastatic pancreatic cancer, clinical characteristics, prognostic factors